Dual NK1/NK3 receptor antagonists
AssigneeHoffmann-La Roche Inc.
InventorsTorsten Hoffmann, Andreas Koblet, Jens-Uwe Peters, Patrick Schnider, Andrew Sleight, Heinz Stadler
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for the treatment of schizophrenia which comprises administering a compound of formula wherein the substituents are as described herein or a pharmaceutically active acid-addition salt thereof. In particular, the invention provides methods for treating both positive and negative symptoms of schizophrenia through dual inhibition of NK1 and NK3 receptors. The invention also provides novel compounds with formula I and methods for preparing compounds of the invention.
Claims8
A compound selected from the group consisting of
A compound selected from the group consisting of
A compound selected from the group consisting of
A compound selected from the group consisting of
A compound selected from the group consisting of
A compound selected from the group consisting of
A compound selected from the group consisting of
Dependencies are inferred from the claim text.